Toward the use of novel alternative methods in epilepsy modeling and drug discovery. [PDF]
Front Neurol, 2023 Miguel Sanz C +4 more
europepmc +1 more source
Epilepsy in Dravet Syndrome-Current and Future Therapeutic Opportunities. [PDF]
J Clin Med, 2023 Gao C +6 more
europepmc +1 more source
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain. [PDF]
Orphanet J Rare Dis, 2023 Poveda JL, Gómez C, Gil A, Badia X.
europepmc +1 more source
Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update. [PDF]
Pharmaceutics, 2022 Parrish RH +5 more
europepmc +1 more source
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders. [PDF]
CNS Drugs, 2023 Malar DS +5 more
europepmc +1 more source
Enhancing glucose metabolism via gluconeogenesis is therapeutic in a zebrafish model of Dravet syndrome. [PDF]
Brain Commun, 2021 Banerji R +5 more
europepmc +1 more source
Flexibility in the Modelling of Comparative Effectiveness in the Absence of Head-to-Head Comparisons in the NICE Single Technology Appraisal of Fenfluramine for Treating Seizures Associated with Lennox-Gastaut Syndrome: An External Assessment Group Perspective. [PDF]
PharmacoeconomicsFernández Coves A +8 more
europepmc +1 more source
Knocking Out Sigma-1 Receptors Reveals Diverse Health Problems. [PDF]
Cell Mol Neurobiol, 2022 Couly S +7 more
europepmc +1 more source
Epilepsy as a Multiscale Network Disorder: Integrating Precision Therapeutics and Emerging Experimental Platforms. [PDF]
PharmaceuticsChang W +5 more
europepmc +1 more source
Sigma-1 receptor and seizures.
Pharmacol Res, 2023 Vavers E, Zvejniece L, Dambrova M.
europepmc +1 more source